X plain presentation
Investigational Device Exemptions 21 CFR Part 812 A Review for OCRA US RAC Study Group September 2005 Ginger Clasby, MS Promedica International [email protected].
FDA Warning Letters - Slide 1
Madeleine Kearney, Gadens Lawyers - Privacy Law Update – How do reforms to the Privacy Act impact the pharmaceutical industry?
Sop for-submission-of-research-projects-15-04-2014
Improving health literacy: challenges for health professionals
Draft -- September, 2009. Randomize Agree? Make Patients Aware of Trial Enroll & Start Treatment Screening Consent Discussion Interest ? Eligible? Agree?
Company LOGO Randomized Trial of a Gatekeeper Program for Suicide Prevention: 1-Year Impact on Secondary School Staff Peter A. Wyman C. Hendricks Brown.
Building Partnerships with Key Populations in HIV Research “ Success and Gaps” Reflections from the Field Dr Joshua Kimani, SWOP UOM – Kenya.
Medicare Qualifying/Deemed Trials: What You Need to Know Theresa M. Shalaby, MSN, RN, CCRP Manager, Clinical Trials Billing Compliance Department of Finance.
Part 1 of 3 Part Series: Informed Consent: The Document Wendy Lloyd, BA, LPN, CIP, CCRP Regulatory Affairs and Compliance Specialist Process Improvement.
Are IRBs Efficient, Effective, or Redundant? David C. Clark, Ph.D. Director, Research Compliance Rush University Center.
